Consolidation with carfilzomib, lenalidomide, and dexamethasone (KRd) following ASCT results in high rates of minimal residual disease negativity and improves bone metabolism, in the absence of bisphosphonates, among newly diagnosed patients with multiple myeloma

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Blood Cancer J
Päätekijät: Gavriatopoulou, Maria, Terpos, Evangelos, Ntanasis-Stathopoulos, Ioannis, Malandrakis, Panagiotis, Eleutherakis-Papaiakovou, Evangelos, Papatheodorou, Athanasios, Kanellias, Nikolaos, Migkou, Magdalini, Fotiou, Despina, Dialoupi, Ioanna, Roussou, Maria, Kokkali, Nikoletta-Aikaterini, Kastritis, Efstathios, Dimopoulos, Meletios A.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: Nature Publishing Group UK 2020
Aiheet:
Correspondence
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC7052253/
https://ncbi.nlm.nih.gov/pubmed/32123158
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/s41408-020-0297-2
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia